Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy
Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy
Nature Medicine 发表了对新诊断多发性骨髓瘤采用四联疗法治疗后最小残留疾病分子预测因子的修正文章。原文已更正并发布在 HTML 和 PDF 版本中。
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04692-0, published online 19 October 2026.
In the version of this article initially published, text in the seventh and eighth sentences of the abstract was incomplete and is now amended in the HTML and PDF versions of the article.
Author information
Author notes
These authors jointly supervised this work: Stéphane Minvielle, Eric Letouzé.
Authors and Affiliations
Nantes Université, INSERM, CNRS, Université d’Angers, CRCI2NA, Nantes, France
Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle & Eric Letouzé
Centre Hospitalier Universitaire de Nantes, Université de Nantes, Nantes, France
Florence Magrangeas, Céline Chevalier, Stéphane Minvielle & Eric Letouzé
Institut de Cancérologie de l’Ouest, Nantes, France
Catherine Guérin-Charbonnel
Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
Benjamin Diamond & Ola Landgren
Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA
Mehmet Kemal Samur
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Mehmet Kemal Samur
Service d’Hématologie, Hôpital Haut Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
Cyrille Hulin
Service d’Hématologie, Centre Hospitalier Universitaire de Dijon, Dijon, France
Denis Caillot
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hematologie, Pierre-Benite, Université Claude Bernard Lyon 1, Lyon, France
Lionel Karlin
Immuno-hématologie, Hôpital Saint Louis, APHP, Université Paris Cité, Paris, France
Bertrand Arnulf
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Nikhil C. Munshi
VA Boston Healthcare System, Boston, MA, USA
Nikhil C. Munshi
Cancer Research Center of Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Toulouse, France
Hervé Avet-Loiseau, Ludovic Martinet & Jill Corre
Institut Universitaire du Cancer, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
Hervé Avet-Loiseau, Ludovic Martinet & Jill Corre
Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse–Oncopole, Service d’Hématologie, Toulouse, France
Aurore Perrot
Service d’Hématologie, Centre Hospitalier Universitaire de Nantes, Nantes, France
Philippe Moreau & Cyrille Touzeau
Authors
- Florence Magrangeas
- Mia Cherkaoui
- Victor Bessonneau-Gaborit
- Jennifer Derrien
- Céline Chevalier
- Catherine Guérin-Charbonnel
- Benjamin Diamond
- Mehmet Kemal Samur
- Cyrille Hulin
- Denis Caillot
- Lionel Karlin
- Bertrand Arnulf
- Ola Landgren
- Nikhil C. Munshi
- Hervé Avet-Loiseau
- Ludovic Martinet
- Jill Corre
- Aurore Perrot
- Philippe Moreau
- Cyrille Touzeau
- Stéphane Minvielle
- Eric Letouzé
Consortia
Intergroupe Francophone du Myélome (IFM)
- Cyrille Hulin
- , Denis Caillot
- , Lionel Karlin
- , Bertrand Arnulf
- , Hervé Avet-Loiseau
- , Jill Corre
- , Aurore Perrot
- , Philippe Moreau
- , Cyrille Touzeau
- & Stéphane Minvielle
Corresponding authors
Correspondence to Stéphane Minvielle or Eric Letouzé.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Magrangeas, F., Cherkaoui, M., Bessonneau-Gaborit, V. et al. Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. Nat Med (2026). https://doi.org/10.1038/s41591-026-04792-x
Published: 03 November 2026
Version of record: 03 November 2026
DOI: https://doi.org/10.1038/s41591-026-04792-x
来源:Nature Medicine · nature.com